Despite all the beneficial effects of IGF-I described up to now and the following ones reporting its role in aging-related pathologies as musculoskeletal, neurodegenerative, cardiovascular diseases, IGF-I has been paradoxically negatively related to lifespan[266, 267], probably due, at least in part, to its downstream molecule Akt and its interactions with FOXO, mTOR and SIRT-1, among others[268, 269]
Simultaneously, these drugs suppress glucagon secretion , a hormone that raises blood glucose levels, further contributing to glycaemic control
Interestingly, about half of users stop taking these medications within a year, a dropout rate similar to lifestyle programs
Anthony RM, MacLeay JM, Jewell DE, Brejda JJ, Gross KL